在急性髓细胞白血病（AML）中通过多参数流式细胞术（MFC）检测最小/可测量残留病（MRD）有许多需要解决的问题，其中之一被反复提起的就是外周血（PB）检测MRD的价值。关于该主题的Pubmed搜索结果主要基于PB中原始细胞的形态学评估，流式检测非常少，这是不正常的。

游客，本帖隐藏的内容需要积分高于 50 才可浏览，您当前积分为 0

文中参考文献：
Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B, et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica. 2007;92:605–11.
Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A, et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia. 2009;23:350–7.
Yu C, Kong QL, Zhang YX, Weng XQ, Wu J, Sheng Y, et al. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia. J Hematol Oncol. 2015;8:48.
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, et al. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol. 2018;36:422–8.